# Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia

> **NCT00278330** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 24 (actual)

## Conditions studied

- Blastic Phase Chronic Myelogenous Leukemia
- Recurrent Adult Acute Lymphoblastic Leukemia
- Recurrent Adult Acute Myeloid Leukemia
- Refractory Anemia With Excess Blasts
- Relapsing Chronic Myelogenous Leukemia
- Untreated Adult Acute Lymphoblastic Leukemia
- Untreated Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** alvocidib
- **DRUG:** vorinostat

## Key facts

- **NCT ID:** NCT00278330
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2009-10
- **Final completion:** —
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00278330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00278330, "Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00278330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*